Eli Lilly plans to make highly anticipated weight-loss pill at new $6.5B Texas plant

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Eli Lilly and Co. plans to build a $6.5 billion manufacturing facility in Houston’s Generation Park. (Rendering provided by Eli Lilly and Co.)

Days after announcing plans for a multibillion dollar manufacturing facility on the east coast, Indianapolis-based drugmaker Eli Lilly and Co. announced Tuesday it plans to build another—this time, in Texas.

The $6.5 billion facility planned for Houston will employ 615 people and will be part of the company’s plans to produce its new, high-profile GLP-1 oral medication, which the company expects to submit to global regulators this year for the treatment of obesity.

Lilly officials made the announcement during a midday news conference in Texas, about a week after the company announced plans for a $5 billion manufacturing facility in Virginia. Both new sites are part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.

The company has not publicly commented on potential locations for the two remaining manufacturing facilities it plans, including any possible further investment in Indiana.

Indiana faces stiff competition in attracting additional investments from the state’s most prominent companies. Lilly said it selected Generation Park, located in the Lake Houston area northeast of the city, from more than 300 applications based on criteria that included “workforce potential, local incentives, access to utilities and transportation and a favorable business environment.”

The new Texas plant will employ engineers, scientists, operational personnel and lab technicians and is expected to generate about 4,000 construction jobs during its build-out, according to Lilly.

“With our highly skilled workforce, low taxes and world-class, business-friendly climate, Texas is the best place for companies like Lilly to grow,” Texas Gov. Greg Abbott said in a written statement.

The plant will focus on making active pharmaceutical ingredients, or API, for the company’s pipeline of small-molecule medicines, including those for cardiometabolic health, oncology, immunology and neuroscience, the company said. Lilly expects the Houston plant to be operational within five years.

Manufacturing weight-loss drugs

Specifically, Lilly said the new facility would produce orforglipron, a new oral medication Lilly is currently anticipating for approval to treat conditions including obesity and diabetes.

Orforglipron is the active glucagon-like peptide-1, or GLP-1, ingredient in a pill taken once a day. Lilly’s current GLP-1 medications—Zepbound for weight loss and Mounjaro for Type 2 diabetes—use the active ingredient tirzepatide and are injected weekly.

“Our new Houston site will enhance Lilly’s ability to manufacture orforglipron at scale and, if approved, help fulfill the medicine’s potential as a metabolic health treatment for tens of millions of people worldwide who prefer the ease of a pill that can be taken without food and water restrictions,” Lilly CEO David Ricks said in a written statement.

“This significant U.S. investment and onshoring of our API production capabilities will ensure faster, more secure access to orforglipron and to other life-changing medicines of the future.”

Lilly said the Houston manufacturing site will use machine learning, artificial intelligence and advanced data analytics. In both the Virginia and Texas announcements, Lilly said it will collaborate with local universities and invest in educational initiatives.

“With this new chemical synthesis facility, we are expanding our vital advanced pharmaceutical capabilities in the U.S. and setting a new global benchmark for innovation and technical leadership in our industry,” Lilly President of Manufacturing Operations Edgardo Hernandez said in a written statement about the new Texas facility.

$50B capital expansion plans

Texas real estate developer McCord said Generation Park, with 4,200 contiguous acres, is in “Houston’s fastest-growing zip code, 77044, (and) provides the resources companies need to grow and thrive.” The site is about 10 minutes from George Bush Intercontinental Airport and 20 minutes from downtown Houston.

Lilly said its capital investment and job figures—$6.5 billion, 615 full-time positions and 4,000 construction jobs—exceeded the company’s initial commitments when submitting for incentives. Indianapolis Business Journal and other media previously reported possible plans for a $5.9 billion plant with about 604 jobs and a potential of more than 2,100 construction jobs.

In February, Lilly announced plans to expand domestic manufacturing across its therapeutic areas by building four pharmaceutical manufacturing sites in the United States. Lilly has said the investments are part of $50 billion in U.S. capital expansion commitments it has made since 2020.

With Virginia and Houston as the confirmed first two locations, Lilly said it will announce the remaining two locations this year.

The drugmaker had previously announced $23 billion in U.S. commitments since 2020. Those include, in Indiana, new facilities at the LEAP Research and Innovation District (LEAP stands for Limitless Exploration/Advanced Pace) and the development of the Lilly Medicine Foundry, both in Lebanon, as well as expansions and updates to several Indianapolis manufacturing facilities.

Please enable JavaScript to view this content.

Story Continues Below

2 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In